COYA 302 for people with ALS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 2 trial will assign adults with ALS to one of two COYA 302 dosing regimens or to placebo for a 24‑week double-blind period, with eligible participants able to enter a blinded active extension for another 24 weeks. COYA 302 is a biologic combination of low‑dose IL‑2 intended to enhance regulatory T cell function and DRL_AB, a biosimilar candidate to abatacept, aimed at suppressing inflammation from activated monocytes and macrophages. The multicenter trial (20–25 sites across the US and Canada) will enroll participants early in their disease course and monitor changes in disease progression and safety measures over time. Key entry criteria include symptom onset within 28 months, ALSFRS‑R ≥35, SVC ≥70% predicted, and a specified baseline rate of progression.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Sporadic or familial ALS, diagnosed as clinically probable, lab-supported probable, or definite ALS according to the revised El Escorial criteria
2. Male or female participants aged 18 to 80
3. Time since onset of ALS symptoms ≤28 months from Screening.
4. ALSFRS-R total score ≥35 at Screening
5. Rate of progression at baseline between -0.5 and -1.5 points per month on ALSFRS-R total score.
6. SVC ≥70% of predicted capacity.
7. Participants receiving riluzole must be on a stable dose for at least 30 days prior to Screening, with intent to stay on stable dosage throughout the study. If not on a stable dose of riluzole for at least 30 days prior to Screening, willing to refrain from initiation of the agent for the duration of the trial.
8. Participants receiving edaravone (intravenous \[IV\] or oral, RADICAVA®) must have completed at least one treatment cycle prior to Screening, with intent to remain on stable dosage throughout the study. If participant has not completed at least one treatment cycle of edaravone at the time of Screening, willing to refrain from initiation of the agent for the duration of the trial.
9. Participants receiving tofersen (QALSODY®) must have completed 90 days of treatment prior to Screening, with intent to remain on stable dosage throughout the study. If participant has not completed at least 90 days of tofersen at the time of Screening, willing to refrain from initiation of the agent for the duration of the trial.

Key Exclusion Criteria:

1. Any clinically significant and/or unstable medical (including active systemic infections requiring treatment), surgical, or psychiatric condition or laboratory abnormality other than ALS, in the judgement of the Investigator.
2. Active suicidality (e.g., any suicide attempts within the past 12 months or any current suicidal intent, including a plan, as assessed by the C-SSRS, score of "YES" on questions 4 or 5; and/or based on clinical evaluation by the Investigator).
3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the upper limit of normal (ULN).
4. Significant renal impairment as determined by estimated glomerular filtration rate (eGFR) of \<60 mL/min.
5. Pre-existing chronic obstructive pulmonary disease or significant pulmonary impairment including those with an FEV1 ≤ 2 liters or \< 75% predicted for height and age, in the judgement of the Investigator.
6. Clinically significant history of cardiac function impairment including cardiac ejection fraction below 40%, ventricular wall motion abnormalities, or coronary artery disease.
7. Any organ allografts.
8. A positive tuberculosis (TB) test indicating a latent TB infection or a positive test for viral hepatitis.
9. Currently receiving or have received abatacept treatment within 75 days prior to Screening.
10. Currently receiving or have received interleukin-2 (IL-2) treatment within 30 days prior to Screening.
11. Currently receiving or expected to receive immunosuppressant therapy (e.g., cyclosporine, sirolimus, tacrolimus, mycophenolate mofetil, systemic steroids) over the course of the study.
12. Planning to receive a live vaccine during the study or within 3 months of discontinuation.
13. Current participation in another interventional clinical trial and/or participation in any investigational medication or device clinical trial within 30 days prior to Screening or 5 half-lives of elimination of the investigational medication, whichever is longer.
14. Previous participation in any COYA 302 (LD rhIL-2 and DRL\_AB) study.
15. Uncontrolled autoimmune condition.
16. Presence of an indwelling central catheter.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• Barrow Neurological Institute
  Phoenix, Arizona, United States Recruiting
• Cedars-Sinai Medical Center
  Los Angeles, California, United States Recruiting
• California Pacific Medical Center
  San Francisco, California, United States Recruiting
• Nova Southeastern University
  Davie, Florida, United States Recruiting
• University of Florida Clinical and Translational Research Center
  Gainesville, Florida, United States Recruiting
• University Of Miami
  Miami, Florida, United States Recruiting

Study contacts

• Study coordinator: Medical Director
• Email: clinicaltrials@coyatherapeutics.com
• Phone: 800-587-8170

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of respiratory impairment in ALS using breathing, MRI, and blood markers

  This study tests whether breathing patterns, MRI changes in the brainstem and spinal cord, and blood markers can reveal early ALS signs, especially in people with genetic risk or early symptoms.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07844590

• Plasmapheresis for ALS with anti-NRIP autoantibody

  This study tests whether a few plasmapheresis sessions can help people with ALS who have anti-NRIP autoantibody by keeping the antibody levels low.

  Recruiting National Taiwan University Hospital · Taipei City, Taipei · NCT07726563

• Implanted brain interface to let people with severe paralysis control assistive devices

  It will try an implanted brain interface that records and stimulates brain signals so adults with severe paralysis can control assistive devices and receive sensory feedback.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07521930

• Do video recordings of multidisciplinary clinics help ALS patients and caregivers?

  This study tests whether providing a video recording of ALS multidisciplinary clinic visits, in addition to written notes, helps patients and their caregivers manage information and feel better about care.

  Recruiting Trustees of Dartmouth College · Scottsdale, Arizona and 6 other locations · NCT07454733

• Measuring Hsp90 levels in the human brain

  This trial tests whether a PET tracer called [11C]HSP990 can measure Hsp90 levels in the brains of healthy adults and people with Parkinson's disease, Alzheimer's disease, or ALS.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaam-Brabant · NCT07380204

• NB-4746 in people with ALS

  This trial tests NB-4746 against placebo to see if it is safe and may help people with ALS.

  Recruiting at 12 sites Phase 1/2 Nura Bio · Concord, New South Wales and 11 other locations · NCT07369076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.